The Human Variable 

VitalGuard™ is CYNAERA’s flagship environmental risk engine for infection-associated chronic conditions (IACCs) such as Long COVID, ME/CFS, POTS, MCAS, and Chronic Lyme. It transforms real-time atmospheric and environmental inputs into predictive flare scores that can inform FEMA incident operations, NIH-funded clinical trials, and CDC-aligned public health programs.

CYNAERA has the first clinical intelligence system designed to simulate and stratify patient response across the full complexity of infection-associated chronic conditions (IACCs) such as ME/CFS, Long COVID, POTS, MCAS, EDS, Lyme, CRPS, and related syndromes. Unlike traditional models that flatten patients into crude categories, CYNAERA builds individualized profiles across 11 stratification axes and integrates them with six mechanistic phenotyping domains.

CYNAERA’s AI simulations analyze 120+ therapeutic candidates across 6 mechanisms, weighting them by patient endotype, Pathos™ severity score, and predicted remission probability. This map provides the first public-facing mechanism reference, while full dosing logic, contraindication overlays, and trial-ready protocols remain licensed.

ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities. Trials should anchor in stabilization before pursuing cure.

Clinical trials for ME/CFS have consistently failed not because therapies were inherently ineffective, but because the system was never built for conditions like ME/CFS and related IACCs. FDA gold-standard trial design assumes predictable progression, uniform subtypes, and tolerance for interventions — none of which apply to ME/CFS The CYNAERA Thesis asserts that repurposed drugs can work for ME/CFS if trials account for post-exertional malaise (PEM),(MCAS), and POTS

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio